J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270009337132v1
49/7/782    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Google Scholar
Right arrow Articles by Xiaoli, D.
Right arrow Articles by Qiang, F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiaoli, D.
Right arrow Articles by Qiang, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

SPECIAL POPULATIONS

Population Pharmacokinetic Study of Cyclosporine in Patients With Nephrotic Syndrome

Du Xiaoli, MS and Fu Qiang, BA

From the Pharmacy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Cyclosporine (CsA) is widely used in the treatment of nephrotic syndrome (NS). A population pharmacokinetic (PopPK) model was developed using trough blood CsA concentration data from 106 patients with NS. The pharmacokinetic analysis was performed using NONMEM with 1-compartment linear model and first-order elimination. Proportional and additive error models were used to describe the interindividual and intraindividual variabilities, respectively. Body weight (WT), serum albumin level (ALB), and combination therapy with rifampicin were found to be the most significant covariates explaining the variability of the apparent clearance (CL/F) of CsA among patients. The final model was as follows: TVCL/F = 34.1 x (WT/67.6)1.08 x (1 + RFA x 0.67) x (1 – ALB x 0.0088); TVV/F = 3.5 x WT; Ka = 1.28 fixed; where RFA = 1 with concurrent rifampicin use and 0 otherwise. The interindividual variabilities of CL/F and V/F were 18% and 27%, respectively. The residual error was 0.064 mg/L. The mean ± SD of CL/F and V/F of the 106 patients were 23.5 ± 7.2 L/h and 232.3 ± 71.5 L, respectively. The reliability and stability of the PopPK model were confirmed by nonparametric bootstrap procedure.


Key Words: Cyclosporinepopulation pharmacokineticsnephrotic syndromeNONMEMBayesian estimation

Address for reprints: Du Xiaoli, MS, Pharmacy Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, #1 Shuaifuyuan, Beijing 100730, China.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American College of Clinical Pharmacology